Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin Delayed Release for Recurrent Acute Diverticulitis
NCT03469050Phase 3Terminated
- Sponsor
- Alfasigma
- Start
- Jul 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of rifaximin in diverticulitis, sponsored by Alfasigma. Started Jul 2018; status: terminated.
02
Drugs
rifaximin
03
Conditions
diverticulitis
Beyond the preview
Go deeper on NCT03469050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03469050.